Author:
Maloney Daniel M,Fernandes Goncalo,Jasim Seema,Williams Tom,Namugenyi Sarah,Carr Michael,Meyer Jennifer R,Sharma Aryan,Marshal Louise,Nunley B Ethan,Xie Hong,Carvajal Mateo,Kunerth Henry D.,Tanmoy Arif,O’Toole Áine,Weixler Amelia,Lanter Kelsey R,Gonzalez Gabrial,Sereewit Jaydee,Guevara Rommel,Loose Matt,Fanning Padraic M.,Benítez Denisse,Fernandez Juan Carlos,Cárdenas Paúl,Hare Daniel,Greninger Alex,Williams Thomas,Nebbia Gaia,Fries Anthony C.,McClure Patrick,Roychoudhury Pavitra,Wang Xiong,Saha Senjuti,Dewar Rebecca,Templeton Kate,Rambaut Andrew
Abstract
AbstractRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LTRIs) in young children and adults over 65, contributing significantly to global healthcare burdens. With the recent approval of multiple pharmacological interventions for RSV, there is an increased demand for efficient, high-throughput sequencing methods to monitor RSV genetic diversity and any potential impact these interventions may have. Here we introduce two novel amplicon-based sequencing schemes designed for RSV A and B, optimised for integration with widespread existing ARTIC sequencing workflows. We demonstrate that these primer schemes can produce high quality genomes from RSV samples across the globe, with eight laboratories in five countries generating complete genomes on both Nanopore and Illumina sequencing platforms. The ability to effectively multiplex these RSV A and B primer schemes, enables streamlined, high-throughput sequencing without prior subtyping. Furthermore, these results provide a snapshot of the circulating diversity of RSV. Phylogenetic analysis of the 882 samples sequenced for this study suggests only minimal geographic clustering of RSV sequences, underscoring the global nature of RSV spread. It also highlights the distinct lineage dynamics seen between RSV A and B. This study represents an advancement in RSV genomics, providing robust tools for global sequencing efforts aimed at tracking RSV evolution and assessing the efficacy of new therapeutic interventions both rapidly and at scale.
Publisher
Cold Spring Harbor Laboratory